Management of Hyperglycemia in NPO Post-Surgical Non-Diabetic Patient

Introduction to Hyperglycemia Management

The American Diabetes Association recommends initiating insulin therapy for non-diabetic patients who are NPO after surgery with persistent hyperglycemia, using basal insulin with correction doses, as sliding-scale monotherapy is ineffective 1, 2

Non-diabetic patients with documented and persistent hyperglycemia after surgery should be treated to the same glycemic goals as patients with known diabetes, particularly when NPO status precludes oral agents 1, 2
Blood glucose values >180-200 mg/dL are associated with worse outcomes in hospitalized surgical patients, including increased infection rates, mortality, length of stay, and ICU requirements 1, 2

The American Diabetes Association explicitly recommends against using sliding-scale short-acting insulin as monotherapy, as this approach is ineffective 1, 2
For NPO patients, continue intravenous insulin infusion if the patient is critically ill or has significantly elevated glucose levels, with a target range of 140-180 mg/dL 1, 2, 3
For non-critically ill NPO patients, initiate basal insulin (long-acting) to provide continuous glucose control, starting with approximately 10 units daily or 0.2-0.3 units/kg if calculating from body weight 3, 4, 5

Monitor blood glucose every 4-6 hours while NPO 6, 7
If using IV insulin and glucose has been stable for 24 hours, calculate total 24-hour IV insulin dose and give 50% as basal long-acting insulin 4, 5

Target blood glucose of 140-180 mg/dL for non-critically ill surgical patients 1, 2, 3
More aggressive targets (110-140 mg/dL) increase hypoglycemia risk without improving outcomes in general surgical patients 3

Patients with new hyperglycemia in the hospital who do not have a prior diabetes diagnosis should have appropriate plans for follow-up testing and care documented at discharge 1, 2
Obtain HbA1c if not done in previous 2-3 months to assess for undiagnosed diabetes 1, 2